The cardiovascular therapy area spans a range of treatment classes including anti-hypertensives, anti-dyslipidemics, anti-thrombotics, hematological preparations and cardiac therapies. Each sub-therapy area is facing a different set of issues and challenges, such as the current generic threat for dyslipidemics and competition from novel therapies in thrombosis. Leading products in these sub-therapy areas have proven to be significant growth drivers for Big Pharma, such as Pfizer’s Lipitor, Sanofi’s Plavix and Lovenox, and Amgen’s Aranesp. The recent emergence of smaller players and increased competition from generics has prompted leading players to engage in alliances and agreements for key drugs to keep pace with the changing market landscape.

‘The Cardiovascular Market Outlook to 2013: Competitive landscape, global market analysis and pipeline analysis’ is a new report published by Business Insights that provides comprehensive coverage of every class of drugs across major cardiovascular indications. Detailed insights into recent key events and future market leaders are also provided, in addition to epidemiological analysis and forecasts for major products over the 2007-13 period. With coverage of over 90% of the total market for cardiovascular products, this report profiles the underlying trends and factors driving the market and identifies the most promising areas of potential growth.

Discover the key market trends and growth drivers of the cardiovascular market, assess the competitive dynamics of leading companies and evaluate the future prospects of major products with this new report...

Some key findings from this report...

• Anti-hypertensives were the highest selling sub-therapeutic category in 2007, with global sales of $52.9bn. Norvasc was the leading anti-hypertensive, with sales of $3.3bn.
• The global market for anticoagulants will experience significant activity over the next two years with the introduction of new drugs including Boehringer Ingelheim’s Pradaxa/Rendix, Bayer- Schering/J&J’s Xarelto, BMS/Pfizer’s apixaban and Eli Lilly/Daiichi’s Effient.
• Crestor has been steadily gaining market share and positive JUPITER trial results will help to further improve its market position. The positive trial data is likely to result in recommended cholesterol treatment goals becoming lowered, and Crestor will be well positioned to capture more patients and expand the market.
• GlaxoSmithKline’s (GSK) acquisition of Reliant Pharma will contribute to GSK having the highest growth amongst the leading players through to 2013. The addition of key drugs such as Lovaza to GSK's portfolio will drive this growth.
• The anti-arrhythmic market is expected to remain a relatively small opportunity, as drug therapy has significant limitations. Multaq from Sanofi-Aventis may become the therapeutic standard in the first-line treatment of chronic atrial fibrillation.

Top five reasons to order your copy today

• Assess patient potential, treatment trends and sales patterns across major cardiovascular diseases over the period 2007-13 within the subtherapy areas of hypertension, dyslipidemia, thrombosis and stroke.
• Measure the market performance and strategic positioning of major pharmaceutical corporations with this report’s evaluation of the franchises and market shares of AstraZeneca, Amgen, BMS, Daiichi Sankyo, GSK, Merck, Novartis, Pfizer and Sanofi-Aventis.
• Discover the market dynamics of the cardiovascular area and understand the impact of recent key events by assessing major market trends, growth drivers and the latest issues affecting R&D.
• Compare the future prospects of key players and forecast sales of leading products across major indications to 2013 with this report’s analysis of sales focus by drug class, currently marketed portfolios, R&D pipelines, and strategy/growth assessments.
• Identify the strategies that offer the greatest success potential within the future cardiovascular market and understand the challenges currently facing companies within this therapeutic area.

Key issues examined in this report...

• Leading cholesterol-lowering drugs show declining sales. Patent expirations have been off-setting positive drivers of growth including recent trial results that support aggressive LDL lowering in broader patient populations. The availability of generic simvastatin has resulted in increased therapeutic substitution and declining brand share.
• Stalling growth of leading hypertension drugs. Angiotensin receptor blockers or ARBs have become the most prescribed antihypertensive class. However after several years of gaining market, growth in the branded ARB category appears to be stalling. A number of studies have shown ARBs to be no more effective than generic ACE inhibitors, most recently the ONTARGET study published in April, 2008
• Novel oral anti-thrombotics threaten leading drugs. Novel drugs in the thrombosis market pipeline are expected to strongly compete with the current market leader Lovenox . The new drugs are orally formulated and are expected to substantially expand the market. Trial data has shown these drugs to be more efficacious without presenting a huge inrease in the risk of bleeding.

Your questions answered...

• Which indications will experience the greatest growth in the global cardiovascular market over the period 2008-13?
• Which companies will become the key players in the cardiovascular area over the period 2009 -13?
• How have recent major product launches from companies such as Gilead and Novartis performed?
• What is the forecast market size and growth rate over the period 2008-2013 across the major cardiovascular indications?
• Which pipeline products offer the highest growth potential?
• What will be the competitive landscape of hypertension, dyslipidemia, thrombosis, hematology and cardiac therapies in 2013?